biotechnology company developing next-generation immunotherapies against cancer that target innate immunity to increase patient cure rates
HEPHAISTOS-Pharma has raised €4.3M across 1 funding round from 4 investors, most recently a Seed round in May 2024. Based in Orsay, France; active in Healthtech. Data as of 7 Aug 2026.
Timing: overdue vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2024-05-16 | Seed | €4.3M |
| Elaia,Fondation Fournier-Majoie,Noshaq,xista science ventures |
| View deal → |
